About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

April 19, 2024
Published by Melanie Hurley Iveagh at April 19, 2024
Categories

Afimmune Announces Partnership in Sickle Cell Disease Research with Pathway to Cures

Dublin, Ireland, 19 April 2024: Afimmune announced today its collaborative partnership with Pathway to Cures (P2C) to support the development of Epeleuton as a potential therapeutic […]
Do you like it?0
Read more

More Press Releases

Publications and Conferences

May 13, 2022
Published by micadmin at May 13, 2022
Categories

EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]
Do you like it?0
Read more

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]